Article, News
FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
Clinical state oncology company Prescient Therapeutics (ASX: PTX) has received the US FDA’s Orphan Drug Designation for its PTX-100 drug, used for cancer treatment. Previously,…
News
Prescient Therapeutics sures supply of cell therapeutic in the hopes of commencing clinical trials
During the second World War, scientists noted that soldiers exposed to nitrogen mustard gas developed interesting hematologic pathology with significantly reduced white blood cell counts….